Nanoparticles in the clinic.
Nanoparticles in the clinic.
复制标题
DOI:
10.1002/btm2.10003
复制
发表时间:
2016-03
影响因子:
7.4
通讯作者:
Mitragotri S
中科院分区:
文献类型:
--
作者:
Anselmo AC;Mitragotri S
Nanoparticle/microparticle‐based drug delivery systems for systemic (i.e., intravenous) applications have significant advantages over their nonformulated and free drug counterparts. For example, nanoparticle systems are capable of delivering therapeutics and treating areas of the body that other delivery systems cannot reach. As such, nanoparticle drug delivery and imaging systems are one of the most investigated systems in preclinical and clinical settings. Here, we will highlight the diversity of nanoparticle types, the key advantages these systems have over their free drug counterparts, and discuss their overall potential in influencing clinical care. In particular, we will focus on current clinical trials for nanoparticle formulations that have yet to be clinically approved. Additional emphasis will be on clinically approved nanoparticle systems, both for their currently approved indications and their use in active clinical trials. Finally, we will discuss many of the often overlooked biological, technological, and study design challenges that impact the clinical success of nanoparticle delivery systems.
登录
查看更多内容
DOI:
10.1016/j.jconrel.2014.03.053
发表时间:
2014-09-28
期刊:
Journal of controlled release : official journal of the Controlled Release Society
影响因子:
--
作者:
Anselmo AC;Mitragotri S
通讯作者:
Mitragotri S
影响因子:
2.2
作者:
Chen, Chia-Hung;Kuo, Min-Liang;Lin, Johnson
通讯作者:
Lin, Johnson
影响因子:
6.2
作者:
Bovier, Patrick A.
通讯作者:
Bovier, Patrick A.
影响因子:
3.3
作者:
Carnevale, Julia;Ko, Andrew H.
通讯作者:
Ko, Andrew H.
影响因子:
10.7
作者:
CUMMINGS, GC;DIXON, J;STEPHENSON, DK
通讯作者:
STEPHENSON, DK